Get started

PHARMA

Biocon breaks out of 4-year consolidationStructure: Breakout from a long-term 4-year consolidation base Volume: Strong expansion indicating institutional participation Momentum: RSI > 70 and holding → bullish trend zone MACD positive and rising → trend confirmation Trend: 9 EMA > 21 EMA > 200 EMA → multi-timeframe trend alignment Sector Strength: Pharma sector outperforming (Sun Pharma, JB Chem, Lupin, Biocon) Broad-based buying visible across sector Bias: Bullish as long as price sustains above breakout levels Invalidation: Close back below breakout zone or loss of EMA/MACD trend
NSE:BIOCONLong
by Punit190
Ajanta Pharma at a Critical Point | Breakout or RejectionAjanta Pharma is currently trading around the ₹2800 mark, which has acted as a strong resistance zone over the past few months. The stock has tested this level 4 to 5 times, indicating significant supply pressure and trader interest at this price point. At this stage, Ajanta Pharma stands at a crucial inflection point: 📈 Bullish Scenario: A clean breakout above ₹2800, especially with volume confirmation, could potentially lead to a 10% upside in the near term, with scope for a 20% rally if momentum sustains. 📉 Bearish Scenario: However, if the stock fails to break through and faces rejection again, we might see a pullback of around 10%, as traders book profits or short near resistance. This setup presents a high-reward trade opportunity with a well-defined risk level, making it a good candidate to keep on your watchlist. Disclaimer: This post is for educational and informational purposes only. I am not a SEBI-registered investment advisor or research analyst. Please do your own research or consult a certified financial advisor before making any investment decisions.
NSE:AJANTPHARMLong
by Chai_trades
Glenmark - Short SetupCMP 1635 on 12.06.25 The chart is self-explanatory. The stock price has increased by approximately 20% over the past month. This time, reaching the confluence area around 1640-1650. If the area around 1650 reacts as resistance again, a correction period will then ensue. Targets may be 1570/1470. The setup will lose significance if it sustains above 1680. The above illustration and analysis are only for learning and sharing purposes; it is not buy or sell recommendations. All the best.
NSE:GLENMARKShort
by anandlive
Fostering global wellnessSenores Pharmaceuticals Ltd - CMP 526.5 About Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities Key Points Business Overview: SPL is global research driven pharmaceutical company which develops and manufactures pharmaceutical products for the Regulated Markets of US, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Company develops and manufactures specialty, underpenetrated and complex pharmaceutical products. It also manufactures criticalcare injectables and APIs Production Facilities: a) Atlanta Plant: Company manufactures oral solids (tablets and capsules) at its plant in Atlanta, USA, with an installed capacity of Tablets ~132.48 million and Capsules ~38.40 million b) Ahmedabad Plant: Company has 3 units where it manufactures Small Vial Parenterals, Oral Solids & Liquids and Beta Lactum in millions annually. It has a total installed capacity of ~1460 Million c) API: Company manufactures API with an annual installed capacity of ~169 MT Clientele: Prasco LLC, Lannett Company Inc., Jubilant Cadista Pharmaceuticals Inc., Alkem Laboratories, Sun Pharmaceuticals Industries, Dr. Reddy’s Laboratories Inc. and Cipla USA Inc. Overseas Presence: Company has presence in ~43 countries including the Regulated Markets of US, Canada and the United Kingdom Segment Revenue - FY24: Regulated Markets ~68%, Emerging Markets ~21%, Critical Care Injectables ~3%, API ~6%, Other Operational income ~3% IPO: Company has launched its IPO for Fresh issue of shares and Offer for sale and it lists on December 30th 2024 Source: Screener.in This is just to boost my confidence. No Suggestions for buying. I will keep checking and updating my mistake if last post gone wrong... Disclosure: I am not SEBI registered. The information provided here is for educational purposes only. I will not be responsible for any of your profit/loss with these suggestions. Consult your financial Adviser before making any decisions.
NSE:SENORESLong
by Alleyshah
Natco Pharma - Enough CorrectionCMP 875 on 22.05.25 The stock price dropped 50% between September 2024 and March 2025. In recent days, it has been consolidating near the 800 levels, which is acting as a support zone, as shown on the chart. MACD shows a likely crossover, too. If it gives an upside move, further targets may be 1080/1180 or more. One has to keep the position size according to the risk management. The setup will go weak if it sustains below 800-775 levels. All these illustrations are only for learning and sharing purposes, not a piece of trading advice in any way. All the best.
NSE:NATCOPHARMLong
by anandlive
3
SEQUENT SCIENTIFIC By KRS Charts8th May 2025 / 10:30 AM Why SEQUENT SCIENTIFIC? 1. Technically it is showing Potential for movement. 2. In Past Already Got More than 50% Returns but important thing is as per Dow Theory it is making Higher Low. 3. In 1D TF multiple Breakouts with Above avg Volume is visible. 4. This is 1M Time Frame , so View is Medium to Long term. T1 is already Achieved in Past but again after Retracement T1 & T2 will be same as before from current price.
NSE:SEQUENTLong
by KRSCharts
15
ALKEM IN BEARS PRESCRIPTION????YES!!!! Chart patterns implies a downward possible move in ALKEM LABS. 1. Every detail given in the chart.....highs and lower highs...lows and lower lows forming a evergreat trading pattern 2. Adding to that, 3 Black crows with good volumes adds probability to the trade. 3. Its been travelling in descending channel pattern...now at the resistance.... Let the Market decide!!!! Let's wait and watch!!!! This is just my opinion....not a tip nor advice!!!!! Thankyou!!!! mmjimm.
NSE:ALKEMShort
by mmjimm
Aurobindo Pharma: Breakout with a Long Opportunity?Aurobindo Pharma is showing signs of a trend reversal on the daily chart. The stock has broken above a descending trendline, supported by strong volumes, signaling a potential bullish move. Key Levels to Watch: Support: ₹1,253 Resistance: ₹1,346 and ₹1,407 Long Opportunity: If the stock sustains above ₹1,300, it offers a good long opportunity with a target of ₹1,407 in the short term. A close above ₹1,407 could open doors to further upside. Traders can consider ₹1,253 as a stop-loss for a risk-managed entry. A decisive move above ₹1,346 will confirm bullish momentum, making this a promising setup for long-term gains.
NSE:AUROPHARMALong
by ayusharya_001
Lupin Ltd: Technical Analysis - December 2024Lupin Ltd (NSE: LUPIN) has displayed an impressive uptrend throughout 2024, supported by a strong ascending trendline (yellow). The stock has experienced healthy corrections along the way, forming a well-defined channel (blue) during its recent consolidation phase. Let’s break it down: Key Observations: Uptrend Continuation: The broader trend remains bullish, with the stock bouncing off the lower boundary of the channel and showing signs of a potential breakout above the resistance. Channel Pattern: A descending channel formation suggests a corrective move within the larger uptrend. The breakout towards the upper end of this channel indicates renewed buying interest. Support & Resistance Levels: Key Support: ₹1,697.50 (red horizontal line), which aligns with a previous demand zone. Immediate Resistance: ₹2,200 - ₹2,250, marking the channel breakout zone. Outlook: A sustained move above ₹2,200 could trigger a new leg of the rally, targeting ₹2,400 and beyond. On the downside, ₹1,900 and ₹1,697.50 will act as crucial supports in case of a pullback. Trading Strategy: Bullish Bias: Buy on dips near ₹2,100-₹2,150 with a stop-loss at ₹1,900. Breakout Play: Enter on a decisive close above ₹2,200 for potential upside. This technical setup provides a promising outlook for Lupin, making it a stock to watch in early 2025.
NSE:LUPINLong
by ayusharya_001
Aurobindo Pharma - Long Trade SetupHello, Auropharma near the resistance level of 1275 . You can enter long when price is crossed above 1275. *Confirmation of Trend Strength: A breakout above resistance indicates strong upward momentum and confirms the existing uptrend. This increases the likelihood of further price appreciation. * Reduced Risk: Trading with the trend minimizes the risk of opposing a large number of market participants who are also betting on the continuation of the uptrend. * Momentum: Breakouts often trigger a surge in buying pressure as traders rush to capitalize on the upward move, further propelling prices higher. * Clear Entry Signal: The breakout provides a well-defined entry point, allowing traders to enter the market with precision and confidence.
NSE:AUROPHARMALong
by piyushbafna000
Aurobindo Pharma - Long Trade SetupHello, Auropharma near the resistance level of 1275 . You can enter long when price is crossed above 1275. *Confirmation of Trend Strength: A breakout above resistance indicates strong upward momentum and confirms the existing uptrend. This increases the likelihood of further price appreciation. * Reduced Risk: Trading with the trend minimizes the risk of opposing a large number of market participants who are also betting on the continuation of the uptrend. * Momentum: Breakouts often trigger a surge in buying pressure as traders rush to capitalize on the upward move, further propelling prices higher. * Clear Entry Signal: The breakout provides a well-defined entry point, allowing traders to enter the market with precision and confidence.
NSE:AUROPHARMALong
by piyushbafna000
ERIS Lifesciences for 25% gainsDate: 3 Dec’24 Symbol: ERIS Timeframe: Weekly ERIS Lifesciences currently seems to be in Wave V of 3 which is heading towards 1960-70 (25% from current price of 1470) as seen in the chart. Wave 4 could then correct back to 1300 levels. The company, in the recently announced September quarter results has posted best ever revenues and operating profits. This is not a prediction but a possible wave count. This is also not a recommendation to trade or invest. Please do your own analysis. HINGLISH VERSION ERIS Lifesciences vartamaan mein Wave 3 ki V mein dikh rahee hai jo 1960-70 (vartamaan keemat 1470 se 25%) kee taraf badh rahee hai jaisa ki chart mein dekh sakte hain. Wave 4 phir 1300 ke star tak neeche aa sakta hai. Company ne haal hee mein ghoshit September quarter results mein ab tak ka sabse achchha revenue aur operating profit darj kiya hai. Yah koi prediction nahin balki sambhaavit Wave count hai. Yah trade lene ya invest karne ki bhi salaah nahi hai. Kripya apana vishleshan khud karein.
NSE:ERISLong
by DhandhaPaani
IPCA LABS - Shorts below 1550 you may think of buying a put option or selling futures if IPCA labs closes below 1550 levels and then you can thank me later by boosting, liking and sharing the post. One of the first modern pharma factory of yesteryears was commissioned by Ipca at Mumbai in 1969. The company was originally promoted by a group of medical professionals and businessmen and was incorporated as 'The Indian Pharmaceutical Combine Association Limited. ' in October 1949. Thank you.
NSE:IPCALABShort
by piyushbafna000